Oli Denne

Cambridge UK

+44 1223 446 400

Oli is a senior associate in our Cambridge office and is part of the Corporate Technology team.

Oli advises a range of companies in the tech and life sciences sectors on a variety of corporate matters, including venture capital investments, fundraisings, M&A and joint ventures.

CV

Since 2023 Senior Associate, Taylor Wessing

2021 - 2023 Associate, Taylor Wessing

2019 - 2020 Associate, Slaughter and May

Karriere

Since 2023 Senior Associate, Taylor Wessing

2021 - 2023 Associate, Taylor Wessing

2019 - 2020 Associate, Slaughter and May

Ausbildung

2019 Admitted as a solicitor in England & Wales

2016 - 2017 GDL & LPC, BPP Law School

2012 - 2015 BA Politics, University of Warwick

Experience

Apollo Therapeutics closes $226.5 million series C financing

We advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.

Press release

News & Insights: Oli Denne

Zu den Insights

Klicken Sie hier für Details

Venture Capital

Advising on the PhysicsX $135 million Series B financing

1. Juli 2025

von Ross McNaughton und Oli Denne

Gesellschaftsrecht/ M&A & Kapitalmärkte

Advising personal care brand, Wild, on its acquisition by Unilever

1. April 2025

von Ed Chapman und Oli Denne

Klicken Sie hier für Details

Gesellschaftsrecht/ M&A & Kapitalmärkte

Shift Bioscience raises US$16 million seed funding

21. Oktober 2024

von Ross McNaughton und Oli Denne

Klicken Sie hier für Details